Transcend Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Transcend Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.12M	Buy	2,503 +490	+24%	+$228K	0.09%	216
2025 Q4	$913K	Sell	2,013 -559	-22%	-$241K	0.07%	245
2025 Q3	$1.01M	Buy	2,572 +828	+47%	+$346K	0.07%	248
2025 Q2	$776K	Sell	1,744 -1,522	-47%	-$701K	0.06%	267
2025 Q1	$1.58M	Buy	3,266 +10	+0.3%	+$4.66K	0.11%	189
2024 Q4	$1.31M	Buy	3,256 +875	+37%	+$406K	0.09%	210
2024 Q3	$1.11M	Buy	2,381 +785	+49%	+$377K	0.07%	248
2024 Q2	$748K	Buy	+1,596	New	+$693K	0.05%	298
2023 Q1	–	Sell	-816	Closed	-$236K	–	526
2022 Q4	$236K	Buy	+816	New	+$249K	0.03%	415

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Transcend Capital Advisors's VRTX Position: Q1 2026 in Review

Transcend Capital Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 24% in Q1 2026, buying an estimated $228K and bringing the position to 2,503 shares worth $1.12M. The position accounts for 0.09% of the portfolio, ranked #216.

Transcend Capital Advisors first reported a position in VRTX in Q4 2022 and has held it in 9 quarters since. The position peaked at $1.58M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Transcend Capital Advisors held 2,503 shares of Vertex Pharmaceuticals worth $1.12M as of Q1 2026.
Transcend Capital Advisors bought 490 Vertex Pharmaceuticals shares in Q1 2026, an estimated $228K.
Vertex Pharmaceuticals made up 0.09% of Transcend Capital Advisors's portfolio in Q1 2026, its #216 holding.
Transcend Capital Advisors first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 9 quarters since.
Transcend Capital Advisors's Vertex Pharmaceuticals position peaked at $1.58M in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Transcend Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.